Home Business Kenya: HIV Drug to Be Made Locally

Kenya: HIV Drug to Be Made Locally

Kenya: HIV Drug to Be Made Locally

What would you do if your body developed resistance to drugs that are supposed to fight the disease ailing you? If this disease then is the deadly HIV, which wreaks havoc a patient’s immune system and leaves it vulnerable to all sorts of opportunistic ailments, you are in big trouble.

But this is the fate that befell about 225,000 Kenyan HIV patients who were using third agent HIV antiretroviral therapy drug efavirenz in their treatment regimen.

To suppress the killer disease, HIV patients follow a treatment regimen where they take a combination of ARV drugs daily that not only reduces their transmission chances but also enables them to live longer, healthier lives.

This treatment normally consists of two nucleoside reverse-transcriptase inhibitor (called NRTIs), usually the drugs tenofovir and either lamivudine or emtricitabine, and a third agent, which could be either a boosted protease inhibitor (bPI), Integrase inhibitors (INIs) or a non-nucleoside reverse-transcriptase inhibitors (NNRTIs).

The drug efavirenz belongs in this third class, and is administered especially when a patient has developed resistance to a drug in any of the other categories.

When a massive number of HIV patients developed resistance to this drug across the world, it was crucial for a new line of drug that would suppress the virus but crucially, at the same time, be affordable and accessible. Enter Dolutegravir (DTG).

Affordable prices